China's Hisun shifts gear to hi-tech and branded in alliances with Enzon and Celsion
This article was originally published in Scrip
Some Chinese pharma companies are apparently no longer satisfied with just manufacturing low-end drugs like generic antibiotics. With more money in hand and an expanding high-quality domestic talent pool, a growing number are eyeing more lucrative fields such as oncology.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.